| |
Tuesday, March 14, 2023 | 2pm ET / 11am PT Join this webinar to hear industry experts across the clinical research space share their perspectives on inefficiencies in the current clinical research space, how to prioritize change, where to begin, how to measure success, and considerations when evaluating and selecting enabling technology. Register now.
|
|
| By Zoey Becker After scoring an accelerated approval for Alzheimer's disease drug Leqembi in January, Eisai and Biogen hope to turn that into a traditional approval by July 6. But an advisory committee will get a chance to vote on the drug first. |
|
|
|
By Max Bayer Merck & Co. has looked to its mid-to-late stage cardiovascular pipeline as a potential goldmine amid the race to replace Keytruda's revenue stream. And a handful of new readouts provide a glimpse into the promise the company is banking on. |
By Andrea Park Amid reports of layoffs within Johnson & Johnson's Janssen pharmaceutical division and outgoing consumer health group, the job cuts have now reached J&J’s medtech division. |
By Teresa Carey This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines. |
|
June 12-14, 2023 | San Diego, CA Digital Pharma Engage is an exclusive, invite-only summit for senior marketing executives from top pharma and biotech companies to come together to network, meet with relevant solution providers and discuss cutting-edge trends in the industry. Apply to Join!
|
|
By Angus Liu When Roche touted data for Polivy in previously untreated large B-cell lymphoma, the company billed the drug as the first potential new treatment standard in nearly two decades. But the FDA sees things differently. |
By James Waldron Anyone looking for a road map out of the biotech bear market will take little comfort from Evaluate Vantage’s latest report. While Big Pharma valuations “regained their mojo” toward the end of last year, the outlook remains bleak for smaller-scaled drug developers. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Fraiser Kansteiner After handing Narasimhan $9 million in performance-based pay in 2021, Novartis' compensation committee slashed the CEO’s award in that category by a whopping 61% last year. The pay cut, spurred by turbulent performance between 2020 and 2022, contrasts sharply with Novartis’ execution during the first three-year stretch under Narasimhan’s lead. |
By Nick Paul Taylor Merck & Co. has joined the emerging race to develop an Epstein-Barr virus vaccine, paying ModeX Therapeutics $50 million upfront and dangling $872.5 million in biobucks for global rights to a preclinical challenger to shots in clinical development at Moderna and the NIH. |
By Nick Paul Taylor Pfizer is once again looking to a diagnostic developer to drum up interest in its COVID-19 drug. Having kicked off the strategy last year through deals with Lucira Health and Roche, the Big Pharma has now partnered with Cue Health to raise awareness of the risks of progressing to severe COVID-19. |
By Fraiser Kansteiner Apotex on Wednesday kicked off a recall of six lots of the glaucoma and ocular hypertension drug brimonidine tartrate ophthalmic solution. The company is acting “out of an abundance of caution” after it found cracks on the caps of certain brimonidine tartrate bottles. Those cracks could jeopardize the drug’s sterility, potentially paving the way for unwanted side effects, Apotex said. |
By Annalee Armstrong It’s been a year since Novartis ventured into orbit with Voyager Therapeutics to find new central nervous system targets. Now, the Big Pharma is ready to go deeper into space with the AAV capsid discovery biotech. |
By Kevin Dunleavy In slashing the cost of its insulin earlier this week by some 70%, Eli Lilly responded quickly to President Joe Biden’s State of the Union appeal to producers of diabetes medicines. But Lilly’s initiative wasn’t enough for relentless pharma industry adversary Sen. Bernie Sanders. In separate letters to the world’s other two premier manufacturers of insulin, Sanofi and Novo Nordisk, Sanders has asked them to also reduce the “outrageous” price of insulin in the United States. |
By Andrea Park CZ Biohub Chicago will focus specifically on developing new technologies equipped with sensors and probes that can draw out high-resolution biological information from human tissue at a molecular level. |
By Zoey Becker After a long road to the FDA finish line for BioMarin, the agency just moved the goal post back by a few months. The new decision date for hemophilia A gene therapy Roctavian is June 30 versus the previous date of March 31. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week. |
|
|---|
|
|
|
Tuesday, March 14, 2023 | 12:00pm ET / 9:00am PT Health equity requires every moving piece of the healthcare ecosystem, including pharma companies. But ensuring a more equitable and an accessible healthcare system starts for pharma at the beginning. It starts with the HCPs you engage for pre-drug launch and marketing; it starts with the site investigators you recruit; it starts with the location and availability of the study. Register now to learn more.
|
|
| WhitepaperLearn how HCP statements influence patient decisions Sponsored by: ZoomRx - HCP-Patient Dialogue Research |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperGet access to the latest life sciences intelligence and stay ahead of the game using Ferma.AI Sponsored by: Ferma.AI, a Product of ZoomRx |
| Whitepaper Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
